Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

River Vision Development Corp.

Latest From River Vision Development Corp.

Horizon Pharma Sees Mid-2019 BLA For Tepro After Solid Phase III TED Data

Horizon Pharma is on track to file its top pipeline asset for regulatory approval this year after its Phase III confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease met primary and secondary endpoints.

Ophthalmic Clinical Trials

Expedited Review Pathways: Three More Breakthroughs, Third RMAT Awarded

US FDA's popular breakthrough therapy designation given to Proteon's vonapanitase for dialysis patients, Synthetic Biologics' ribaxamase to prevent C. difficile infection, and River Vision's teprotumumab for thyroid eye disease; Vericel's cell therapy for heart failure is designated a regenerative medicine advanced therapy.

Review Pathway Regulation

Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission

Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.

Deals M & A

Horizon's Poor Primary Care Performance Overshadows River Vision Buy

Horizon's deal to buy River Vision to bolster its orphan product pipeline is cast into the shade by a disappointing first quarter performance for its primary care business.

Deals Sales & Earnings
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • River Vision Development Corp.
  • Senior Management
  • Dave Madden, CEO
  • Contact Info
  • River Vision Development Corp.
    Phone: (212) 582-8400
    1 Rockefeller Plaza
    Ste. 1204
    New York, NY 10020
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register